Even though the responsiveness to IL-2 in Treg from SLE patients showed no impairment, the clinical response was transient and declined almost to baseline levels in between the cycles, suggesting that the cyclic treatment modality may be suboptimal. Here, IL2 is linked to systemic lupus erythematosus.